Myeloma XI trial results: personalising treatment options for patients

The Myeloma XI trial is one of the largest trials to date in multiple myeloma. In one of its three randomisation stages, it investigated lenalidomide maintenance versus observation in patients with newly diagnosed multiple myeloma. In this video, Dr Martin Kaiser discusses some of the most recent results of the trial, and the importance of identifying the right subgroup of patients that will benefit from maintenance therapy.

The views expressed in this video are those of the speaker.

UK/NP/1806/0035(1)s - February 2019

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.